Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
License, Collaboration, and Other Revenue: $1.8 million in Q3 2024, compared to $1.9 million in Q3 2023. Cost of Goods Sold: $14.2 million in Q3 2024, down from $18 million in Q3 2023. Research and Development Expense: $8.5 million in Q3 2024, down from $13.3 million in Q3 2023. SG&A Expense: $26.5 million in Q3 2024, up from $22.7 million in Q3 2023. Net Loss: $20 million in Q3 2024, compared to $14.5 million in Q3 2023. Cash and Cash Equivalents: $34 million at the end of Q3 2024, with pro forma cash of $43.7 million after ATM facility proceeds. Warning! GuruFocus has detected 6 Warning Signs with AKBA. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Akebia Therapeutics Inc ( NASDAQ:AKBA ) is preparing for the U.S. market availability of Vafseo, expected in January 2025, with significant progress on launch initiatives. The company has secured TDAPA reimbursement from CMS and rece
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePR Newswire
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
AKBA
Earnings
- 11/7/24 - Miss
AKBA
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- AKBA's page on the SEC website